Jefferies Global Healthcare Conference in London
Jefferies Global Healthcare Conference in London Date: November 17-20, 2025 To view the webcast, please click here.
Press Release
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
✨ Onyx Summary A new Harris Poll survey commissioned by ImmunityBio finds that most U.S. patients with non-muscle invasive bladder cancer receive limited discussion of treatment options despite heavy reliance on healthcare providers for guidance, and many seek alternatives to chemotherapy, including immunotherapy. The results underscore a communication gap in
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
✨ Onyx Summary Legend Biotech opened a new 31,000-square-foot R&D facility in Philadelphia to support expansion of its next-generation cell therapy pipeline, adding approximately 55 research staff and strengthening its U.S. footprint. The site enhances the company’s innovation capabilities alongside existing New Jersey operations and aligns
enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants
✨ Onyx Summary enGene priced its underwritten public offering of 12.6 million common shares and 2.7 million pre-funded warrants, raising approximately $130 million in gross proceeds, with a 30-day overallotment option available to underwriters. The financing, conducted under the company’s effective shelf registration, is expected to close on
Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access
✨ Onyx Summary Guardant Health launched the 34-member Single Namespace Working Group to establish an open standard for exabyte-scale data interoperability, creating a unified framework that links globally distributed data into a single namespace. The consortium’s transition to OASIS positions the standard for broad adoption, aiming to streamline data access
Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights
✨ Onyx Summary Legend Biotech reported third-quarter results highlighted by continued revenue growth for CARVYKTI, strengthened by updated survival data, expanded commercial manufacturing in Europe, and progress across its global clinical programs. The company ended the quarter with approximately $1.0 billion in cash and reduced its net loss year over
enGene Announces Proposed Public Offering of Common Shares
✨ Onyx Summary enGene initiated an underwritten public offering of its common shares, with all shares offered by the company and an additional 15% overallotment option available to underwriters, subject to market conditions. The offering will be conducted under enGene’s effective shelf registration and supports ongoing advancement of its non-viral
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
✨ Onyx Summary Kyverna Therapeutics reported third-quarter progress across its neuroimmunology CAR T franchise, including positive interim Phase 2 data in generalized myasthenia gravis, advancement of its registrational trials in stiff person syndrome and gMG, and continued expansion into additional autoimmune indications, supported by upcoming milestones such as an early-2026 SPS
Neochromosome and GlobalBio Launch Pre-Transformed Antibody Libraries in Switchable Yeast Platform
✨ Onyx Summary Neochromosome and GlobalBio introduced an integrated platform that combines ALTHEA antibody libraries with the neoSwitch yeast system to enable rapid, in-house biologics discovery with streamlined transitions from display to secretion. The collaboration reduces the cost and duration of antibody screening by eliminating traditional library construction steps and providing
Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months
✨ Onyx Summary enGene reported additional preliminary Phase 2 LEGEND data for detalimogene voraplasmid in high-risk BCG-unresponsive NMIBC, showing a 63% complete response rate at any time and improved 6-month CR rates under an amended protocol, alongside a favorable safety profile across 125 patients. The company has aligned its primary endpoint
Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference
✨ Onyx Summary Lexicon Pharmaceuticals announced that its management will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on November 18, with live and archived access available through the company’s investor events page. THE WOODLANDS, TEXAS, NOV. 11, 2025 — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
✨ Onyx Summary Kyverna Therapeutics announced that CEO Warner Biddle will present at the Jefferies Global Healthcare Conference in London on November 17, 2025, at 1:00 p.m. GMT. A live and archived webcast of the presentation will be available on the company’s investor relations website for 90 days.
SpyGlass Pharma Announces Positive 36-Month First-in-Human and 3-Month Phase I/II Trial Results for Its Novel BIM-IOL System
✨ Onyx Summary SpyGlass Pharma reported positive data from two clinical trials of its Bimatoprost Drug Pad-IOL System (BIM-IOL System) for patients with open-angle glaucoma or ocular hypertension, showing sustained intraocular pressure reduction and elimination of topical drops. The 36-month FIH study and interim Phase I/II results demonstrated strong safety,
enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial
✨ Onyx Summary enGene Holdings announced it will host a conference call and webcast on November 11, 2025, to present new preliminary data from the pivotal cohort of its ongoing LEGEND trial evaluating detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer. Supporting materials, including a slide deck and replay, will be
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results
✨ Onyx Summary Perspective Therapeutics reported a third-quarter 2025 net loss of $26.0 million and ended the period with $174 million in cash, providing funding into late 2026. The company advanced multiple clinical programs, including strong interim safety and efficacy data for [212Pb]VMT-α-NET in neuroendocrine tumors, ongoing studies of
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
✨ Onyx Summary Lexicon Pharmaceuticals announced new data from the SOTA P CARDIA trial presented at AHA 2025 showing that sotagliflozin significantly improved cardiac structure, diastolic function, exercise capacity, and quality of life in heart failure patients with preserved ejection fraction and without diabetes. The findings, led by Mount Sinai’s